Company: SYRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001641172-25-023235
Chunk: 6

Company: Syra Health Corp
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 1
Chunk 6
---
 6,108 
  
    Accrued expenses 
     (105,630) 
     (24,761)
  
    Operating lease liability 
     (277,029) 
     (63,199)
  
    Net cash provided by/(used in) operating activities 
     85,754 
     (2,304,012)

    CASH FLOWS FROM INVESTING ACTIVITIES 

    Purchase of property and equipment 
     -  
     (11,111)
  
    Net cash used in investing activities 
     -  
     (11,111)

    CASH FLOWS FROM FINANCING ACTIVITIES 

    Proceeds received on exercise of warrants 
     14,800  
     850,129 
  
    Repayments on notes payable 
     (190,035) 
     (220,729)
  
    Net cash provided by/(used in) financing activities 
     (175,235) 
     629,400 

    NET CHANGE IN CASH AND CASH EQUIVALENTS 
     (89,481) 
     (1,685,723)
  
    CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 
     2,395,405  
     3,280,075 
  
    CASH AND CASH EQUIVALENTS AT END OF PERIOD 
    $2,305,924  
    $1,594,352 

    SUPPLEMENTAL INFORMATION: 

    Interest paid 
    $7,087  
    $7,806 
  
    Income taxes paid 
    $-  
    $- 
  
    NON-CASH INVESTING AND FINANCING ACTIVITIES: 

    Conversion of Class B common stock to Class A common stock 
    $2,333  
    $- 
  
    Initial recognition of right-of-use asset and lease liability 
    $-  
    $351,193 
  
    Prepaid asset financed with note payable 
    $123,866  
    $150,159 

See
accompanying notes to condensed unaudited financial statements.

F-5

SYRA
HEALTH CORP.

NOTES
TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

Note
1 – Nature of Business and Significant Accounting Policies

Nature